Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Mezigdomide and Elranatamab for Relapsed And/or Refractory Multiple Myeloma
Phase 1
Recruiting
Conditions
Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
Drug: Elranatamab
Drug: Mezigdomide
Drug: Dexamethasone
Subscribe
First Posted Date
2024-10-17
Last Posted Date
2024-12-24
Lead Sponsor
YOUNGIL KOH
Target Recruit Count
75
Registration Number
NCT06645678
Locations
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy